Cordyceps fungi have been studied across a range of physiological contexts, from oxygen utilization to kidney health. In recent years, a growing body of preclinical research has turned its attention to another area: blood glucose regulation and metabolic function. While human clinical trials remain limited, early findings from animal and cell-based studies suggest that certain Cordyceps-derived compounds may influence glucose metabolism through several identifiable mechanisms.
What Is Cordyceps and Why Might It Affect Blood Sugar?
Cordyceps is a genus of parasitic fungi found throughout Asia, with Cordyceps militaris and Cordyceps sinensis being the most researched species. The fruiting bodies and mycelium of these fungi contain bioactive compounds including polysaccharides, cordycepin (3′-deoxyadenosine), adenosine, and sterols.
Among these, polysaccharides have received the most attention in the context of blood glucose. Polysaccharides are complex carbohydrate chains that appear in many medicinal fungi and have been studied for their potential to modulate immune function, gut microbiota composition, and metabolic pathways. In Cordyceps, these compounds may interact with insulin signaling cascades and influence how cells take up and process glucose.
Polysaccharides and Glucose Metabolism: What Studies Show
A 2023 study published in Molecules examined polysaccharides isolated from different parts of Cordyceps cicadae, including the sclerotia, spores, and fruiting body. Researchers tested the extracts in both cell-based models and in type 2 diabetes model mice. The spore powder polysaccharide fraction demonstrated the strongest activity, improving body weight and glucose and lipid metabolism in the diabetic mouse model. Investigators proposed that the underlying mechanism may involve activation of the PI3K/Akt signaling pathway, a key route in insulin-mediated glucose uptake by cells.[1]
These are preclinical findings, and the leap from rodent models to human physiology requires considerable caution. Nonetheless, identifying a plausible molecular mechanism is considered an important step in building the evidence base for a compound’s potential effects.
Gut Microbiota as a Possible Intermediary
A 2023 study published in Frontiers in Nutrition investigated polysaccharides from Cordyceps cicadae in high-fat diet and streptozocin-induced diabetic mice. The research found that treatment with the polysaccharide fraction was associated with reduced blood glucose, improved antioxidant markers, and reduced inflammatory indicators. Of particular interest was the apparent effect on gut microbiota composition: treated animals showed a reduced Firmicutes-to-Bacteroidetes ratio and increased abundance of genera such as Bacteroides and Parabacteroides, both associated with improved metabolic outcomes in the literature. The researchers also noted changes in tryptophan metabolite production and GLP-1 secretion, suggesting that gut-derived signaling may play a role in the observed effects.[2]
This gut-microbiota angle is consistent with findings from other medicinal mushrooms. For a broader look at how functional fungi interact with gut bacteria, see our overview of Maitake Mushroom: What Research Says About Blood Sugar and Immunity, which explores similar prebiotic and metabolic mechanisms in a closely related context.
Metabolic Syndrome and Protective Effects
A 2021 study published in Chemistry and Biodiversity examined two polysaccharide fractions from Cordyceps cicadae in rats fed a high-fructose, high-fat diet. Over an 11-week intervention period, both fractions were associated with reductions in body weight, serum glucose levels, insulin resistance markers, and serum lipid profiles. Liver function enzyme levels and pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6 were also reduced in treated animals. The authors concluded that the polysaccharide fractions may offer protective effects against diet-induced metabolic disturbances.[3]
It is worth noting that the doses used in these animal studies were administered in a controlled experimental setting and should not be interpreted as guidance for human supplementation. These findings describe effects observed under specific research conditions.
Cordycepin and Diabetic Complications
Cordycepin, the nucleoside compound found in Cordyceps militaris, has been investigated separately from the polysaccharide fraction. Research published in Molecular Immunology in 2025 focused specifically on diabetic nephropathy, a complication of long-term high blood glucose, and found that cordycepin may reduce markers of renal dysfunction and inflammatory signaling in high-glucose-exposed kidney cells. While this study was focused on kidney complications rather than blood glucose levels directly, it adds to the broader picture of how Cordyceps-derived compounds may interact with glucose-related disease processes.[4]
What Is Still Unknown
The current evidence for Cordyceps and blood sugar management is based almost entirely on animal and cell-based studies. The specific species, extraction methods, and dosing contexts used in laboratory settings often differ substantially from commercially available supplements. Human clinical trials examining Cordyceps and glycemic control are limited in number and scope.
Additionally, the research to date has focused primarily on Cordyceps cicadae, a species less commonly found in consumer products than Cordyceps militaris or cultivated mycelium-based products. Whether findings from one species translate to another remains an open question in the literature.
Individuals managing blood sugar conditions or taking medications for diabetes or insulin sensitivity should consult a qualified healthcare provider before adding any mushroom supplement to their routine, as potential interactions and individual variability are important considerations.
Summary
Preclinical research suggests that polysaccharides derived from certain Cordyceps species may influence glucose metabolism through pathways involving insulin signaling, gut microbiota modulation, and inflammatory regulation. These findings are preliminary and drawn from animal studies, with human clinical evidence still limited. Cordyceps remains an active area of research for metabolic health, and future well-designed clinical trials will be necessary to clarify whether these effects translate to meaningful outcomes in humans.
References
- Wang Y, et al. Structural Characterization and Hypoglycemic Function of Polysaccharides from Cordyceps cicadae. Molecules. 2023;28(2):526. PMID: 36677586
- Wang Y, et al. Cordyceps cicadae polysaccharides alleviate hyperglycemia by regulating gut microbiota and its metabolites in high-fat diet/streptozocin-induced diabetic mice. Front Nutr. 2023;10:1203430. PMID: 37599693
- Zhang X, et al. Alleviation of Liver Dysfunction, Oxidative Stress, and Inflammation Underlines the Protective Effects of Polysaccharides from Cordyceps cicadae on High Sugar/High Fat Diet-Induced Metabolic Syndrome in Rats. Chem Biodivers. 2021;18(5):e2100065. PMID: 33738897
- Han W, et al. Cordycepin ameliorates high glucose-induced proliferation, inflammation, and extracellular matrix deposition in glomerular mesangial cells through Smad7-dependent manner. Mol Immunol. 2025;183:156-171. PMID: 40373638
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Functional mushroom supplements are not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before starting any new supplement, particularly if you have a medical condition or take prescription medications.
